Results 21 to 30 of about 2,974,682 (398)

Effects of KF19514, a Phosphodiesterase 4 and 1 Inhibitor, on Bronchial Inflammation and Remodeling in a Murine Model of Chronic Asthma

Allergology International, 2009
Background: Phosphodiesterase 4 selective inhibitor may prevent airway inflammation and remodeling. Objective: The aim of this study was to investigate the effects of KF19514, a phosphodiesterase 4 and 1 dual inhibitor, on chronic airway inflammation and
Toshiyuki Kita, Masaki Fujimura, Shigeharu Myou, Kazuyoshi Watanabe, Yuko Waseda, Shinji Nakao   +5 more
doaj   +1 more source

Phosphodiesterase-4 Inhibition in the Management of Psoriasis

Pharmaceutics, 2023
Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatments for psoriasis, phosphodiesterase-4 (PDE4) inhibitors are emerging with expanding options.
E. Crowley, M. Gooderham
semanticscholar   +1 more source

Pharmacological analysis of the feeding response of codling moth (Cydia pomonella; Lepidoptera: Tortricidae) neonates to bitter compounds

European Journal of Entomology, 2017
Feeding in codling moth neonate caterpillars was inhibited by 0.67 mM and 2.24 mM concentrations of denatonium benzoate. This inhibitory effect was abolished by phospholipase C inhibitor, U-73122 and the phosphodiesterase inhibitor, Rolipram. Quinine and
Maciej A. PSZCZOLKOWSKI
doaj   +1 more source

Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus

Nature Communications, 2023
Pemphigus vulgaris is a life-threatening blistering skin disease caused by autoantibodies which destabilize cell adhesion of keratinocytes. The phosphodiesterase 4 inhibitor apremilast prevents skin blistering by stabilizing the keratin filament ...
Anna M. Sigmund, Markus Winkler, Sophia Engelmayer, Daniela Kugelmann, Desalegn T. Egu, Letyfee S. Steinert, Michael Fuchs, Matthias Hiermair, Mariya Y. Radeva, Franziska C. Bayerbach, Elisabeth Butz, Stefan Kotschi, Christoph Hudemann, Michael Hertl, Sunil Yeruva, Enno Schmidt, Amir S. Yazdi, Kamran Ghoreschi, Franziska Vielmuth, Jens Waschke   +19 more
doaj   +1 more source

Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]

, 2017
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo, CECI GALANOS, Roberta, Crescioli, Clara, Di Luigi, Luigi, Duranti, Guglielmo, Sabatini, Stefania, Sansone, Andrea, Sansone, Massimiliano, Sgrò, Paolo   +8 more
core   +1 more source

Research of cGMP- and cAMP-dependent intracellular signaling systems in the insulin-mediated regulation of platelets aggregation activity in patients with heart failure and metabolic disturbances

Бюллетень сибирской медицины, 2012
Data of the study of cGMP- and cAMP-dependent intracellular signaling systems in the insulin-mediated regulation of the platelet aggregation activity in 25 patients with DM2 and heart failure are presented.
O. N. Ogurkova, T. Ye. Suslova, A. V. Sitoshevsky, O. A. Koshelskaya   +3 more
doaj   +1 more source

DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1 [PDF]

, 2007
DNA single-strand breaks (SSBs) are the commonest DNA lesions arising spontaneously in cells, and if not repaired may block transcription or may be converted into potentially lethal/clastogenic DNA double-strand breaks (DSBs).
Arnaudeau, Avemann, Barzilai, Bendixen, Caldecott, Caldecott, Cheng, Chrencik, Christiansen, Clements, Connelly, Culmsee, Daroui, Date, Davies, Davies, Davies, de Boer, Deng, D’Arpa, El-Khamisy, Flangas, Furuta, Godthelp, Hinz, Holm, Horwitz, Hsiang, Inamdar, Interthal, Interthal, Interthal, K.W. Caldecott, Kroeger, Lanza, Lesher, Liao, Lindahl, Liu, Mol, Moreira, Morris, Nitiss, Nouspikel, O’Driscoll, Parsons, Plo, Pommier, Pommier, Pommier, Poot, Pouliot, Pouliot, Pourquier, Pourquier, Pourquier, Pourquier, Pourquier, Rideout, Ryan, Ryan, S.F. El-Khamisy, Sarkander, Sarkander, Shao, Stewart, Strumberg, Takashima, Taylor, Thompson, van Waardenburg, Vance, Vidal, Vierck, Wang, Whitehouse, Wilson, Wu, Wu, Yan, Yang, Zhou, Zhou   +82 more
core   +1 more source

Editorial [PDF]

, 2016
No abstract ...
Baillie, George S.
core   +1 more source

A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease

Haematologica, 2019
The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with pleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to ...
J. Mcarthur, N. Svenstrup, Chunsheng Chen, A. Fricot, C. Carvalho, J. Nguyen, Phong Nguyen, Anna I. Parachikova, Fuad A. Abdulla, G. Vercellotti, O. Hermine, Dave Edwards, J. Ribeil, J. Belcher, T. Maciel   +14 more
semanticscholar   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources